Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 790

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial

Parekh, Dipen J, Reis, Isildinha M, Castle, Erik P, Gonzalgo, Mark L, Woods, Michael E, Svatek, Robert S, Weizer, Alon Z, Konety, Badrinath R, Tollefson, Mathew, Krupski, Tracey L, Smith, Norm D, Shabsigh, Ahmad, Barocas, Daniel A, Quek, Marcus L, Dash, Atreya, Kibel, Adam S, Shemanski, Lynn, Pruthi, Raj S, Montgomery, Jeffrey Scott, Weight, Christopher J, Sharp, David S, Chang, Sam S, Cookson, Michael S, Gupta, Gopal N, Gorbonos, Alex, Uchio, Edward M, Skinner, Eila, Venkatramani, Vivek, Soodana-Prakash, Nachiketh, Kendrick, Kerri, Smith, Joseph A, Thompson, Ian M · 2018 · The Lancet

Abstract

BACKGROUND Radical cystectomy is the surgical standard for invasive bladder cancer. Robot-assisted cystectomy has been proposed to provide similar oncological outcomes with lower morbidity. We aimed to compare progression-free survival in patients with bladder cancer treated with open cystectomy and robot-assisted cystectomy. METHODS The RAZOR study is a randomised, open-label, non-inferiority, phase 3 trial done in 15 medical centres in the USA. Eligible participants (aged ≥18 years) had biopsy-proven clinical stage T1-T4, N0-N1, M0 bladder cancer or refractory carcinoma in situ. Individuals who had previously had open abdominal or pelvic surgery, or who had any pre-existing health conditions that would preclude safe initiation or maintenance of pneumoperitoneum were excluded. Patients were centrally assigned (1:1) via a web-based system, with block randomisation by institution, stratified by type of urinary diversion, clinical T stage, and Eastern Cooperative Oncology Group performance status, to receive robot-assisted radical cystectomy or open radical cystectomy with extracorporeal urinary diversion. Treatment allocation was only masked from pathologists. The primary endpoint was 2-year progression-free survival, with non-inferiority established if the lower bound of the one-sided 97·5% CI for the treatment difference (robotic cystectomy minus open cystectomy) was greater than -15 percentage points. The primary analysis was done in the per-protocol population. Safety was assessed in the same population. This trial is registered with ClinicalTrials.gov, number NCT01157676. FINDINGS Between July 1, 2011, and Nov 18, 2014, 350 participants were randomly assigned to treatment. The intended treatment was robotic cystectomy in 176 patients and open cystectomy in 174 patients. 17 (10%) of 176 patients in the robotic cystectomy group did not have surgery and nine (5%) patients had a different surgery to that they were assigned. 21 (12%) of 174 patients in the open cystectomy group did not have surgery and one (1%) patient had robotic cystectomy instead of open cystectomy. Thus, 302 patients (150 in the robotic cystectomy group and 152 in the open cystectomy group) were included in the per-protocol analysis set. 2-year progression-free survival was 72·3% (95% CI 64·3 to 78·8) in the robotic cystectomy group and 71·6% (95% CI 63·6 to 78·2) in the open cystectomy group (difference 0·7%, 95% CI -9·6% to 10·9%; pnon-inferiority=0·001), indicating non-inferiority of robotic cystectomy. Adverse events occurred in 101 (67%) of 150 patients in the robotic cystectomy group and 105 (69%) of 152 patients in the open cystectomy group. The most common adverse events were urinary tract infection (53 [35%] in the robotic cystectomy group vs 39 [26%] in the open cystectomy group) and postoperative ileus (33 [22%] in the robotic cystectomy group vs 31 [20%] in the open cystectomy group). INTERPRETATION In patients with bladder cancer, robotic cystectomy was non-inferior to open cystectomy for 2-year progression-free survival. Increased adoption of robotic surgery in clinical practice should lead to future randomised trials to assess the true value of this surgical approach in patients with other cancer types. FUNDING National Institutes of Health National Cancer Institute.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)30996-6

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 790

Metadata

Authors
Parekh, D. J., Reis, I. M., Castle, E. P., Gonzalgo, M. L., Woods, M. E., Svatek, R. S., Weizer, A. Z., Konety, B. R., Tollefson, M., Krupski, T. L., Smith, N. D., Shabsigh, A., Barocas, D. A., Quek, M. L., Dash, A., Kibel, A. S., Shemanski, L., Pruthi, R. S., Montgomery, J. S., Weight, C. J., Sharp, D. S., Chang, S. S., Cookson, M. S., Gupta, G. N., Gorbonos, A., Uchio, E. M., Skinner, E., Venkatramani, V., Soodana-Prakash, N., Kendrick, K., Smith, J. A., & Thompson, I. M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-06
Volume
391
Issue
10139
Pages
2525-2536
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2809685212
Cited by
790
References
15
FWCI
80.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)30996-6
The paper
Parekh, D. J., Reis, I. M., Castle, E. P., Gonzalgo, M. L., Woods, M. E., Svatek, R. S., Weizer, A. Z., Konety, B. R., Tollefson, M., Krupski, T. L., Smith, N. D., Shabsigh, A., Barocas, D. A., Quek, M. L., Dash, A., Kibel, A. S., Shemanski, L., Pruthi, R. S., Montgomery, J. S., . . . Thompson, I. M. (2018). Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)30996-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.